Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection

Nexus Pharmaceuticals announces FDA approval of its Tacrolimus Injection 5 mg/mL, the first and only vial formulation available, enhancing treatment options for patients requiring immunosuppressive therapy.
Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP

Nexus Pharmaceuticals announces FDA approval of its Methylene Blue Injection, USP, for the treatment of acquired methemoglobinemia, reinforcing its commitment to delivering critical, life-saving medications.